ArticleBMC medical imaging2026
Can multi-phase contrast-enhanced CT be used to differentiate between intra-abdominal and retroperitoneal fat-poor liposarcoma and leiomyosarcoma?
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThis study aimed to assess the diagnostic performance of contrast-enhanced CT in differentiating intra-abdominal and retroperitoneal fat-poor liposarcoma (FPLPS) from leiomyosarcoma (LMS).
methodsA retrospective analysis was conducted on patients with pathologically confirmed intra-abdominal or retroperitoneal non-uterine LMS and FPLPS. Twelve CT imaging features were assessed, and quantitative parameters, including arterial enhancement fraction (AEF) and extracellular volume fraction (ECV), were calculated. Multivariate logistic regression identified independent predictors, and a combined nomogram model was constructed. Model performance was assessed using ROC analysis, calibration, and decision curve analysis.
resultsA total of 56 intra-abdominal or retroperitoneal sarcomas, including non-uterine LMS (n = 27) and FPLPS (n = 29). AEF (OR = 1.07, P = 0.006), mean tumor diameter (OR = 1.29, P = 0.040), and patchy enhancement (OR = 7.58, P = 0.021) were independent predictors for distinguishing FPLPS from LMS. The dynamic nomogram ( https://liexiantu1.shinyapps.io/dynom/ .) demonstrated excellent diagnostic accuracy (AUC = 0.885) with satisfactory calibration, and clinical utility.
conclusionsQuantitative (AEF) and qualitative (tumor size and enhancement pattern) of CT features reliably distinguish FPLPS from LMS in intra-abdominal and retroperitoneal locations. The nomogram offers a practical, non-invasive tool to support preoperative diagnosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.